Journal article icon

Journal article

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Abstract:

Background
Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour.

Methods
For the open-label, randomised, controlled QUASAR 2 trial, which was done at 170 hospitals in seven countries, we recruited patients aged 18 years or older with WHO performance status scores of 0 or 1 who had und...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/S1470-2045(16)30172-3

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
Expand authors...
Oxford NIHR Comprehensive Biomedical Research Centre More from this funder
Australasian Gastro-Intestinal Trials Group More from this funder
Publisher:
Lancet Publisher's website
Journal:
Lancet Oncology Journal website
Volume:
17
Issue:
11
Pages:
1543–1557
Publication date:
2016-09-19
Acceptance date:
2016-05-17
DOI:
ISSN:
1470-2045 and 1474-5488
Source identifiers:
652738
Pubs id:
pubs:652738
UUID:
uuid:442dd21f-5928-4919-a4c3-15b3b734b655
Local pid:
pubs:652738
Deposit date:
2016-10-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP